Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nuvation BioNUVB -5.52%33 Receivables Turnover is 4.29 as of Mar. 2026. GuruFocus rates NUVB with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 841 Biotechnology companies, Nuvation Bio ranks better than 87.04% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Nuvation Bio's Revenue for the
three
months ended in Mar. 2026 was $83.2 Mil. Nuvation Bio's average Accounts Receivable for the
three
months ended in Mar. 2026 was $19.4 Mil.
Hence, Nuvation Bio's Receivables Turnover for the
three
months ended in Mar. 2026 was 4.29.
Nuvation Bio (NYSE:NUVB) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Nuvation Bio Receivables Turnover Related Terms
Nuvation Bio Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Nuvation Bio's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NUVB vs IOVA, SLS, COAG: Receivables Turnover Comparison
For the Biotechnology subindustry, Nuvation Bio's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvation Bio's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio (NUVB) has a Receivables Turnover of 4.29 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Nuvation Bio and its competitors. According to the industry distribution chart, Nuvation Bio ranks #109 out of 841 companies in the Biotechnology industry, placing it in the top 13%.
Is Nuvation Bio's Receivables Turnover too high?
Nuvation Bio's current Receivables Turnover is 4.29. The Biotechnology industry median Receivables Turnover is 5.29. Nuvation Bio's value of 4.29 is 18.9% below this industry median. Based on the distribution chart, Nuvation Bio ranks #109 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nuvation Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Nuvation Bio's Receivables Turnover compare to IOVA and SLS?
According to the Biotechnology industry distribution chart, Nuvation Bio ranks #109 out of 841 companies for Receivables Turnover. This places Nuvation Bio in the top 13% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.29. Nuvation Bio's value of 4.29 is 18.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nuvation Bio's current Receivables Turnover of 4.29 is 18.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Nuvation Bio and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuvation Bio's current Receivables Turnover is 4.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvation Bio stock overvalued right now?
Nuvation Bio (NUVB) has a current Receivables Turnover of 4.29. The current Receivables Turnover is 4.29 and 18.9% below the Biotechnology industry median of 5.29. Nuvation Bio's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Nuvation Bio (NUVB), the current Receivables Turnover is 4.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
33GF Score
Get the complete analysis for NUVB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NUVB has been successfully added to your 
